{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:51:01Z","timestamp":1772725861340,"version":"3.50.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T00:00:00Z","timestamp":1315872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s11940-011-0146-5","type":"journal-article","created":{"date-parts":[[2011,9,12]],"date-time":"2011-09-12T05:11:03Z","timestamp":1315804263000},"source":"Crossref","is-referenced-by-count":22,"title":["Autoimmune Neuromuscular Disorders in Childhood"],"prefix":"10.1007","volume":"13","author":[{"given":"Hugh J.","family":"McMillan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basil T.","family":"Darras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter B.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,13]]},"reference":[{"issue":"Suppl 1","key":"146_CR1","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/ana.410370703","volume":"37","author":"MC Dalakas","year":"1995","unstructured":"Dalakas MC. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. Ann Neurol. 1995;37 Suppl 1:S2\u201313.","journal-title":"Ann Neurol"},{"issue":"2","key":"146_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/ana.410380208","volume":"38","author":"PG Oomes","year":"1995","unstructured":"Oomes PG, Jacobs BC, Hazenberg MP, Banffer JR, van der Meche FG. Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barre syndrome: evidence of molecular mimicry. Ann Neurol. 1995;38(2):170\u20135.","journal-title":"Ann Neurol"},{"issue":"4","key":"146_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0887-8994(88)90042-2","volume":"4","author":"AA al-Qudah","year":"1988","unstructured":"al-Qudah AA, Shahar E, Logan WJ, Murphy EG. Neonatal Guillain-Barre syndrome. Pediatr Neurol. 1988;4(4):255\u20136.","journal-title":"Pediatr Neurol"},{"issue":"3","key":"146_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1067\/mpd.2003.115","volume":"142","author":"J Vajsar","year":"2003","unstructured":"Vajsar J, Fehlings D, Stephens D. Long-term outcome in children with Guillain-Barre syndrome. J Pediatr. 2003;142(3):305\u20139.","journal-title":"J Pediatr"},{"issue":"4","key":"146_CR5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mus.880150415","volume":"15","author":"DY Bradshaw","year":"1992","unstructured":"Bradshaw DY, Jones Jr HR. Guillain-Barre syndrome in children: clinical course, electrodiagnosis, and prognosis. Muscle Nerve. 1992;15(4):500\u20136.","journal-title":"Muscle Nerve"},{"issue":"6","key":"146_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0022-3476(99)70297-0","volume":"134","author":"DK Nguyen","year":"1999","unstructured":"Nguyen DK, Agenarioti-Belanger S, Vanasse M. Pain and the Guillain-Barre syndrome in children under 6\u00a0years old. J Pediatr. 1999;134(6):773\u20136.","journal-title":"J Pediatr"},{"issue":"9","key":"146_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1212\/WNL.0b013e31820e7b62","volume":"76","author":"J Roodbol","year":"2011","unstructured":"Roodbol J, de Wit MC, Walgaard C, de Hoog M, Catsman-Berrevoets CE, Jacobs BC. Recognizing Guillain-Barre syndrome in preschool children. Neurology 2011;76(9):807\u201310.","journal-title":"Neurology"},{"issue":"Suppl","key":"146_CR8","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1002\/ana.410270707","volume":"27","author":"AK Asbury","year":"1990","unstructured":"Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol. 1990;27(Suppl):S21\u201324.","journal-title":"Ann Neurol"},{"issue":"8","key":"146_CR9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00381-010-1197-8","volume":"26","author":"A Yikilmaz","year":"2010","unstructured":"Yikilmaz A, Doganay S, Gumus H, Per H, Kumandas S, Coskun A. Magnetic resonance imaging of childhood Guillain-Barre syndrome. Childs Nerv Syst. 2010;26(8):1103\u20138.","journal-title":"Childs Nerv Syst"},{"issue":"6","key":"146_CR10","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/mus.20520","volume":"33","author":"K Nagasawa","year":"2006","unstructured":"Nagasawa K, Kuwabara S, Misawa S, Fujii K, Tanabe Y, Yuki N, et al. Electrophysiological subtypes and prognosis of childhood Guillain-Barre syndrome in Japan. Muscle Nerve. 2006;33(6):766\u201370.","journal-title":"Muscle Nerve"},{"issue":"6","key":"146_CR11","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.61.6.736","volume":"61","author":"RA Hughes","year":"2003","unstructured":"Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, et al. Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61(6):736\u201340.","journal-title":"Neurology"},{"issue":"3","key":"146_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3109\/00365549509019016","volume":"27","author":"N Gurses","year":"1995","unstructured":"Gurses N, Uysal S, Cetinkaya F, Islek I, Kalayci AG. Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome. Scand J Infect Dis. 1995;27(3):241\u20133.","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"146_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1542\/peds.2004-1324","volume":"116","author":"R Korinthenberg","year":"2005","unstructured":"Korinthenberg R, Schessl J, Kirschner J, Monting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: a randomized trial. Pediatrics. 2005;116(1):8\u201314.","journal-title":"Pediatrics"},{"issue":"4","key":"146_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/adc.74.4.281","volume":"74","author":"R Korinthenberg","year":"1996","unstructured":"Korinthenberg R, Monting JS. Natural history and treatment effects in Guillain-Barre syndrome: a multicentre study. Arch Dis Child. 1996;74(4):281\u20137.","journal-title":"Arch Dis Child"},{"issue":"6","key":"146_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/ana.10205","volume":"51","author":"B Buchwald","year":"2002","unstructured":"Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol. 2002;51(6):673\u201380.","journal-title":"Ann Neurol"},{"key":"146_CR16","doi-asserted-by":"crossref","unstructured":"Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2002(2):CD001798.","DOI":"10.1002\/14651858.CD001798"},{"issue":"1","key":"146_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ana.410280112","volume":"28","author":"MA Epstein","year":"1990","unstructured":"Epstein MA, Sladky JT. The role of plasmapheresis in childhood Guillain-Barre syndrome. Ann Neurol. 1990;28(1):65\u20139.","journal-title":"Ann Neurol"},{"issue":"6","key":"146_CR18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41(6):789\u201396.","journal-title":"Ann Neurol"},{"issue":"8093","key":"146_CR19","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","volume":"2","author":"RA Hughes","year":"1978","unstructured":"Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978;2(8093):750\u20133.","journal-title":"Lancet"},{"issue":"5","key":"146_CR20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1212\/WNL.41.5.617","volume":"41","author":"Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP)","year":"1991","unstructured":"Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology. 1991;41(5):617\u20138.","journal-title":"Neurology"},{"issue":"Pt 6","key":"146_CR21","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1093\/brain\/110.6.1617","volume":"110","author":"PA McCombe","year":"1987","unstructured":"McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain. 1987;110(Pt 6):1617\u201330.","journal-title":"Brain"},{"issue":"2","key":"146_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0960-8966(01)00286-3","volume":"12","author":"Y Nevo","year":"2002","unstructured":"Nevo Y, Topaloglu H. 88th ENMC international workshop: childhood chronic inflammatory demyelinating polyneuropathy (including revised diagnostic criteria), Naarden, The Netherlands, December 8\u201310, 2000. Neuromuscul Disord. 2002;12(2):195\u2013200.","journal-title":"Neuromuscul Disord"},{"issue":"Pt 7","key":"146_CR23","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/brain\/122.7.1383","volume":"122","author":"AJ Duggins","year":"1999","unstructured":"Duggins AJ, McLeod JG, Pollard JD, Davies L, Yang F, Thompson EO, et al. Spinal root and plexus hypertrophy in chronic inflammatory demyelinating polyneuropathy. Brain. 1999;122(Pt 7):1383\u201390.","journal-title":"Brain"},{"issue":"6","key":"146_CR24","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S0960-8966(00)00119-X","volume":"10","author":"MM Ryan","year":"2000","unstructured":"Ryan MM, Grattan-Smith PJ, Procopis PG, Morgan G, Ouvrier RA. Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome. Neuromuscul Disord. 2000;10(6):398\u2013406.","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"146_CR25","first-page":"1793","volume":"21","author":"M Cellerini","year":"2000","unstructured":"Cellerini M, Salti S, Desideri V, Marconi G. MR imaging of the cauda equina in hereditary motor sensory neuropathies: correlations with sural nerve biopsy. AJNR Am J Neuroradiol. 2000;21(10):1793\u20138.","journal-title":"AJNR Am J Neuroradiol"},{"key":"146_CR26","doi-asserted-by":"crossref","unstructured":"Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2009(1):CD001797. This Cochrane Database review found that IVIG was better than placebo for the treatment of CIDP. IVIG, plasma exchange, and steroids were found to be equally efficacious for this disease. The studies analyzed were performed primarily on adult patients.","DOI":"10.1002\/14651858.CD001797.pub2"},{"issue":"4","key":"146_CR27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1055\/s-2007-973489","volume":"30","author":"R Korinthenberg","year":"1999","unstructured":"Korinthenberg R. Chronic inflammatory demyelinating polyradiculoneuropathy in children and their response to treatment. Neuropediatrics. 1999;30(4):190\u20136.","journal-title":"Neuropediatrics"},{"issue":"2","key":"146_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pediatrneurol.2006.09.012","volume":"36","author":"E Rossignol","year":"2007","unstructured":"Rossignol E, D'Anjou G, Lapointe N, Haddad E, Vanasse M. Evolution and treatment of childhood chronic inflammatory polyneuropathy. Pediatr Neurol. 2007;36(2):88\u201394.","journal-title":"Pediatr Neurol"},{"issue":"12","key":"146_CR29","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/(SICI)1097-4598(199712)20:12<1569::AID-MUS12>3.0.CO;2-W","volume":"20","author":"Z Simmons","year":"1997","unstructured":"Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. Muscle Nerve. 1997;20(12):1569\u201375.","journal-title":"Muscle Nerve"},{"issue":"6","key":"146_CR30","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1212\/WNL.41.6.828","volume":"41","author":"VV Vedanarayanan","year":"1991","unstructured":"Vedanarayanan VV, Kandt RS, Lewis Jr DV, DeLong GR. Chronic inflammatory demyelinating polyradiculoneuropathy of childhood: treatment with high-dose intravenous immunoglobulin. Neurology. 1991;41(6):828\u201330.","journal-title":"Neurology"},{"issue":"1","key":"146_CR31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1212\/WNL.47.1.98","volume":"47","author":"Y Nevo","year":"1996","unstructured":"Nevo Y, Pestronk A, Kornberg AJ, Connolly AM, Yee WC, Iqbal I, et al. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology. 1996;47(1):98\u2013102.","journal-title":"Neurology"},{"issue":"1","key":"146_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0022-510X(97)00216-5","volume":"154","author":"N Hattori","year":"1998","unstructured":"Hattori N, Ichimura M, Aoki S, Nagamatsu M, Yasuda T, Kumazawa K, et al. Clinicopathological features of chronic inflammatory demyelinating polyradiculoneuropathy in childhood. J Neurol Sci. 1998;154(1):66\u201371.","journal-title":"J Neurol Sci"},{"issue":"Pt 4","key":"146_CR33","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","volume":"119","author":"AF Hahn","year":"1996","unstructured":"Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain. 1996;119(Pt 4):1067\u201377.","journal-title":"Brain"},{"issue":"2","key":"146_CR34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"RA Hughes","year":"2008","unstructured":"Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136\u201344.","journal-title":"Lancet Neurol"},{"issue":"3","key":"146_CR35","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/BF00868527","volume":"243","author":"N Thompson","year":"1996","unstructured":"Thompson N, Choudhary P, Hughes RA, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 1996;243(3):280\u20135.","journal-title":"J Neurol"},{"issue":"4","key":"146_CR36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","volume":"56","author":"JR Mendell","year":"2001","unstructured":"Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2001;56(4):445\u20139.","journal-title":"Neurology"},{"issue":"1","key":"146_CR37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/jnnp.56.1.36","volume":"56","author":"M Vermeulen","year":"1993","unstructured":"Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1993;56(1):36\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Pt 4","key":"146_CR38","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","volume":"119","author":"AF Hahn","year":"1996","unstructured":"Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain. 1996;119(Pt 4):1055\u201366.","journal-title":"Brain"},{"issue":"6","key":"146_CR39","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/ana.410360607","volume":"36","author":"PJ Dyck","year":"1994","unstructured":"Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36(6):838\u201345.","journal-title":"Ann Neurol"},{"issue":"2","key":"146_CR40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ana.1088","volume":"50","author":"R Hughes","year":"2001","unstructured":"Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50(2):195\u2013201.","journal-title":"Ann Neurol"},{"issue":"3","key":"146_CR41","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7326\/0003-4819-84-3-304","volume":"84","author":"AS Fauci","year":"1976","unstructured":"Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976;84(3):304\u201315.","journal-title":"Ann Intern Med"},{"issue":"1","key":"146_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/mus.20075","volume":"30","author":"MB Bromberg","year":"2004","unstructured":"Bromberg MB, Carter O. Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data. Muscle Nerve. 2004;30(1):20\u201337.","journal-title":"Muscle Nerve"},{"issue":"8","key":"146_CR43","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1212\/WNL.35.8.1173","volume":"35","author":"PJ Dyck","year":"1985","unstructured":"Dyck PJ, O'Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology. 1985;35(8):1173\u20136.","journal-title":"Neurology"},{"issue":"8","key":"146_CR44","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s004150050135","volume":"244","author":"A Lindner","year":"1997","unstructured":"Lindner A, Schalke B, Toyka KV. Outcome in juvenile-onset myasthenia gravis: a retrospective study with long-term follow-up of 79 patients. J Neurol. 1997;244(8):515\u201320.","journal-title":"J Neurol"},{"issue":"4","key":"146_CR45","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/(SICI)1097-4598(199804)21:4<454::AID-MUS3>3.0.CO;2-8","volume":"21","author":"MH Barnett","year":"1998","unstructured":"Barnett MH, Pollard JD, Davies L, McLeod JG. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1998;21(4):454\u201360.","journal-title":"Muscle Nerve"},{"issue":"3","key":"146_CR46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pediatrneurol.2009.03.016","volume":"41","author":"MO Herguner","year":"2009","unstructured":"Herguner MO, Incecik F, Altunbasak S. Cyclosporin treatment in three children with chronic inflammatory demyelinating neuropathy. Pediatr Neurol. 2009;41(3):223\u20135.","journal-title":"Pediatr Neurol"},{"issue":"3","key":"146_CR47","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0161-6420(99)00138-4","volume":"107","author":"P Mullaney","year":"2000","unstructured":"Mullaney P, Vajsar J, Smith R, Buncic JR. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. Ophthalmology. 2000;107(3):504\u201310.","journal-title":"Ophthalmology"},{"issue":"2","key":"146_CR48","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-0404.2006.00646.x","volume":"114","author":"VV Ashraf","year":"2006","unstructured":"Ashraf VV, Taly AB, Veerendrakumar M, Rao S. Myasthenia gravis in children: a longitudinal study. Acta Neurol Scand. 2006;114(2):119\u201323.","journal-title":"Acta Neurol Scand"},{"issue":"7","key":"146_CR49","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1212\/WNL.44.7.1208","volume":"44","author":"PI Andrews","year":"1994","unstructured":"Andrews PI, Massey JM, Howard Jr JF, Sanders DB. Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology. 1994;44(7):1208\u201314.","journal-title":"Neurology"},{"issue":"8","key":"146_CR50","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0960-8966(98)00077-7","volume":"8","author":"A Evoli","year":"1998","unstructured":"Evoli A, Batocchi AP, Bartoccioni E, Lino MM, Minisci C, Tonali P. Juvenile myasthenia gravis with prepubertal onset. Neuromuscul Disord. 1998;8(8):561\u20137.","journal-title":"Neuromuscul Disord"},{"issue":"25","key":"146_CR51","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","volume":"330","author":"DB Drachman","year":"1994","unstructured":"Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797\u2013810.","journal-title":"N Engl J Med"},{"issue":"5","key":"146_CR52","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1212\/WNL.43.5.977","volume":"43","author":"PI Andrews","year":"1993","unstructured":"Andrews PI, Massey JM, Sanders DB. Acetylcholine receptor antibodies in juvenile myasthenia gravis. Neurology. 1993;43(5):977\u201382.","journal-title":"Neurology"},{"issue":"4","key":"146_CR53","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/mus.21195","volume":"39","author":"LM Chiang","year":"2009","unstructured":"Chiang LM, Darras BT, Kang PB. Juvenile myasthenia gravis. Muscle Nerve. 2009;39(4):423\u201331.","journal-title":"Muscle Nerve"},{"issue":"6","key":"146_CR54","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.pediatrneurol.2008.11.014","volume":"40","author":"B Anlar","year":"2009","unstructured":"Anlar B, Yilmaz V, Saruhan-Direskeneli G. Long remission in muscle-specific kinase antibody-positive juvenile myasthenia. Pediatr Neurol. 2009;40(6):455\u20136.","journal-title":"Pediatr Neurol"},{"issue":"1","key":"146_CR55","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/088307380201700123","volume":"17","author":"CY Tsao","year":"2002","unstructured":"Tsao CY, Mendell JR, Friemer ML, Kissel JT. Lambert-Eaton myasthenic syndrome in children. J Child Neurol. 2002;17(1):74\u20136.","journal-title":"J Child Neurol"},{"issue":"11","key":"146_CR56","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","volume":"68","author":"L Zinman","year":"2007","unstructured":"Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837\u201341.","journal-title":"Neurology"},{"issue":"11","key":"146_CR57","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","volume":"62","author":"P Gajdos","year":"2005","unstructured":"Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol. 2005;62(11):1689\u201393.","journal-title":"Arch Neurol"},{"key":"146_CR58","doi-asserted-by":"crossref","unstructured":"Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2008(1):CD002277.","DOI":"10.1002\/14651858.CD002277.pub3"},{"issue":"6","key":"146_CR59","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","volume":"97","author":"C Lindberg","year":"1998","unstructured":"Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand. 1998;97(6):370\u20133.","journal-title":"Acta Neurol Scand"},{"issue":"7","key":"146_CR60","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17(7):893\u2013902.","journal-title":"Eur J Neurol"},{"issue":"3","key":"146_CR61","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","volume":"15","author":"RM Pascuzzi","year":"1984","unstructured":"Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15(3):291\u20138.","journal-title":"Ann Neurol"},{"issue":"2","key":"146_CR62","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1212\/WNL.34.2.170","volume":"34","author":"A Sghirlanzoni","year":"1984","unstructured":"Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F. Myasthenia gravis: prolonged treatment with steroids. Neurology. 1984;34(2):170\u20134.","journal-title":"Neurology"},{"issue":"1","key":"146_CR63","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1600-0404.1991.tb04899.x","volume":"84","author":"V Cosi","year":"1991","unstructured":"Cosi V, Citterio A, Lombardi M, Piccolo G, Romani A, Erbetta A. Effectiveness of steroid treatment in myasthenia gravis: a retrospective study. Acta Neurol Scand. 1991;84(1):33\u20139.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"146_CR64","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000116785","volume":"32","author":"A Evoli","year":"1992","unstructured":"Evoli A, Batocchi AP, Palmisani MT, Lo Monaco M, Tonali P. Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol. 1992;32(1):37\u201343.","journal-title":"Eur Neurol"},{"issue":"6","key":"146_CR65","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/ncpneuro0810","volume":"4","author":"S Sathasivam","year":"2008","unstructured":"Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol. 2008;4(6):317\u201327.","journal-title":"Nat Clin Pract Neurol"},{"key":"146_CR66","doi-asserted-by":"crossref","unstructured":"A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group. J Neurol Neurosurg Psychiatry. 1993;56(11):1157\u201363.","DOI":"10.1136\/jnnp.56.11.1157"},{"issue":"6","key":"146_CR67","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50(6):1778\u201383.","journal-title":"Neurology"},{"key":"146_CR68","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","volume":"681","author":"RS Tindall","year":"1993","unstructured":"Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993;681:539\u201351.","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"146_CR69","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s004150050141","volume":"244","author":"DM Bonifati","year":"1997","unstructured":"Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J Neurol. 1997;244(9):542\u20137.","journal-title":"J Neurol"},{"issue":"4","key":"146_CR70","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1600-0404.2005.00378.x","volume":"111","author":"D Lavrnic","year":"2005","unstructured":"Lavrnic D, Vujic A, Rakocevic-Stojanovic V, Stevic Z, Basta I, Pavlovic S, et al. Cyclosporine in the treatment of myasthenia gravis. Acta Neurol Scand. 2005;111(4):247\u201352.","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"146_CR71","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000085833","volume":"53","author":"Y Nagane","year":"2005","unstructured":"Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y. Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study. Eur Neurol. 2005;53(3):146\u201350.","journal-title":"Eur Neurol"},{"key":"146_CR72","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1196\/annals.1405.000","volume":"1132","author":"JM Ponseti","year":"2008","unstructured":"Ponseti JM, Gamez J, Azem J, Lopez-Cano M, Vilallonga R, Armengol M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci. 2008;1132:254\u201363.","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"146_CR73","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/jnnp.2006.093567","volume":"78","author":"WS Baek","year":"2007","unstructured":"Baek WS, Bashey A, Sheean GL. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J Neurol Neurosurg Psychiatry. 2007;78(7):771.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"146_CR74","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400\u20136.","journal-title":"Neurology"},{"issue":"23","key":"146_CR75","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011;76(23):2017\u201323.","journal-title":"Neurology"},{"issue":"1","key":"146_CR76","first-page":"161","volume":"46","author":"A Kamel","year":"2009","unstructured":"Kamel A, Essa M. Effectiveness of prethymectomy plasmapheresis on the short-term outcome of non-thymomatous generalized myasthenia gravis. Egypt J Neurol Psychiatr Neurosurg. 2009;46(1):161\u20138.","journal-title":"Egypt J Neurol Psychiatr Neurosurg"},{"issue":"4","key":"146_CR77","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1177\/0883073808325653","volume":"24","author":"MM Tracy","year":"2009","unstructured":"Tracy MM, McRae W, Millichap JG. Graded response to thymectomy in children with myasthenia gravis. J Child Neurol. 2009;24(4):454\u20139.","journal-title":"J Child Neurol"},{"issue":"5","key":"146_CR78","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/ana.410130506","volume":"13","author":"M Rodriguez","year":"1983","unstructured":"Rodriguez M, Gomez MR, Howard Jr FM, Taylor WF. Myasthenia gravis in children: long-term follow-up. Ann Neurol. 1983;13(5):504\u201310.","journal-title":"Ann Neurol"},{"issue":"3","key":"146_CR79","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/088307389000500313","volume":"5","author":"C Adams","year":"1990","unstructured":"Adams C, Theodorescu D, Murphy EG, Shandling B. Thymectomy in juvenile myasthenia gravis. J Child Neurol. 1990;5(3):215\u20138.","journal-title":"J Child Neurol"},{"issue":"10","key":"146_CR80","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/rheumatology\/kel099","volume":"45","author":"LJ McCann","year":"2006","unstructured":"McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)\u2013clinical characteristics of children recruited within the first 5\u00a0yr. Rheumatology (Oxford). 2006;45(10):1255\u201360.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"146_CR81","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1177\/000992288702601101","volume":"26","author":"LC Miller","year":"1987","unstructured":"Miller LC, Michael AF, Kim Y. Childhood dermatomyositis. Clinical course and long-term follow-up. Clin Pediatr (Phila). 1987;26(11):561\u20136.","journal-title":"Clin Pediatr (Phila)"},{"issue":"3","key":"146_CR82","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T","volume":"43","author":"AM Huber","year":"2000","unstructured":"Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43(3):541\u20139.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"146_CR83","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344\u20137.","journal-title":"N Engl J Med"},{"issue":"4","key":"146_CR84","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S0889-857X(02)00024-8","volume":"28","author":"AV Ramanan","year":"2002","unstructured":"Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am. 2002;28(4):833\u201357.","journal-title":"Rheum Dis Clin North Am"},{"issue":"9631","key":"146_CR85","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/S0140-6736(08)60955-1","volume":"371","author":"BM Feldman","year":"2008","unstructured":"Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371(9631):2201\u201312.","journal-title":"Lancet"},{"issue":"5","key":"146_CR86","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.berh.2009.07.007","volume":"23","author":"LR Wedderburn","year":"2009","unstructured":"Wedderburn LR, Rider LG. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol. 2009;23(5):665\u201378.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"146_CR87","first-page":"1198","volume":"25","author":"LM Pachman","year":"1998","unstructured":"Pachman LM, Hayford JR, Chung A, Daugherty CA, Pallansch MA, Fink CW, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol. 1998;25(6):1198\u2013204.","journal-title":"J Rheumatol"},{"issue":"9","key":"146_CR88","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3899\/jrheum.090953","volume":"37","author":"E Stringer","year":"2010","unstructured":"Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, Lindsley CB, Ota S, Pilkington C, Reed AM, Scuccimarri R, Feldman BM. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol. 2010;37(9):1953\u201361.","journal-title":"J Rheumatol"},{"issue":"2","key":"146_CR89","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","volume":"62","author":"AM Huber","year":"2010","unstructured":"Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, Pachman LM, Pilkington C, Reed AM, Rennebohm RM, Rider LG, Wallace CA, Feldman BM. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken) 2010;62(2):219\u201325.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"146_CR90","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0022-3476(83)80706-9","volume":"103","author":"SL Bowyer","year":"1983","unstructured":"Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr. 1983;103(6):882\u20138.","journal-title":"J Pediatr"},{"issue":"2","key":"146_CR91","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s100670050032","volume":"19","author":"S Al-Mayouf","year":"2000","unstructured":"Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol. 2000;19(2):138\u201341.","journal-title":"Clin Rheumatol"},{"issue":"11","key":"146_CR92","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1002\/art.21378","volume":"52","author":"AV Ramanan","year":"2005","unstructured":"Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52(11):3570\u20138.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"146_CR93","first-page":"1545","volume":"16","author":"NY Olson","year":"1989","unstructured":"Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol. 1989;16(12):1545\u20137.","journal-title":"J Rheumatol"},{"issue":"10","key":"146_CR94","first-page":"2498","volume":"27","author":"SM Al-Mayouf","year":"2000","unstructured":"Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol. 2000;27(10):2498\u2013503.","journal-title":"J Rheumatol"},{"issue":"12","key":"146_CR95","first-page":"2436","volume":"24","author":"A Reiff","year":"1997","unstructured":"Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol. 1997;24(12):2436\u201343.","journal-title":"J Rheumatol"},{"issue":"8646","key":"146_CR96","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S0140-6736(89)92456-2","volume":"1","author":"J Heckmatt","year":"1989","unstructured":"Heckmatt J, Hasson N, Saunders C, Thompson N, Peters AM, Cambridge G, et al. Cyclosporin in juvenile dermatomyositis. Lancet. 1989;1(8646):1063\u20136.","journal-title":"Lancet"},{"issue":"4","key":"146_CR97","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/rheumatology\/keh082","volume":"43","author":"P Riley","year":"2004","unstructured":"Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004;43(4):491\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"146_CR98","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archderm.142.1.65","volume":"142","author":"JC Edge","year":"2006","unstructured":"Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142(1):65\u20139.","journal-title":"Arch Dermatol"},{"issue":"9","key":"146_CR99","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00431-004-1497-7","volume":"163","author":"A Yamada","year":"2004","unstructured":"Yamada A, Ohshima Y, Omata N, Yasutomi M, Mayumi M. Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A. Eur J Pediatr. 2004;163(9):561\u20132.","journal-title":"Eur J Pediatr"},{"issue":"9","key":"146_CR100","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1002\/art.22856","volume":"56","author":"MA Cooper","year":"2007","unstructured":"Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007;56(9):3107\u201311.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"146_CR101","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jpeds.2009.09.008","volume":"156","author":"DM Levy","year":"2010","unstructured":"Levy DM, Bingham CA, Kahn PJ, Eichenfield AH, Imundo LF. Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids. J Pediatr. 2010;156(2):302\u20137.","journal-title":"J Pediatr"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-011-0146-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-011-0146-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-011-0146-5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-011-0146-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T09:38:05Z","timestamp":1712828285000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-011-0146-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,13]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["146"],"URL":"https:\/\/doi.org\/10.1007\/s11940-011-0146-5","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,13]]},"article-number":"590"}}